Publication details

Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors

Authors

FAZIO Nicola MARTINI Jean-Francois CROITORU Adina E. SCHENKER Michael LI Sherry ROSBROOK Brad FERNANDEZ Kathrine TOMÁŠEK Jiří THIIS-EVENSEN Espen KULKE Matthew RAYMOND Eric

Year of publication 2019
Type Article in Periodical
Magazine / Source Future Oncology
MU Faculty or unit

Faculty of Medicine

Citation
Web http://dx.doi.org/10.2217/fon-2018-0934
Doi http://dx.doi.org/10.2217/fon-2018-0934
Keywords biomarkers; efficacy; pancreatic neuroendocrine tumor; sunitinib; VEGF
Description Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.

You are running an old browser version. We recommend updating your browser to its latest version.

More info